{
  "PMC": "6275920",
  "DOI": "10.2478/s11658-010-0009-1",
  "PMID": "20336406",
  "PMCID": "PMC6275920",
  "title": "The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues.",
  "year": 2010,
  "source_url": "https://europepmc.org/article/PMC/PMC6275920",
  "source": "MED",
  "abstract_text": "Lifeguard (LFG) is an anti-apoptotic protein that inhibits Fas-mediated death in tumour cells. However, the molecular function of human LFG in the carcinogenesis of human breast cells is uncertain. We studied the expression and function of endogenous LFG in four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D and HS 578T), a human breast epithelial cell line (HS 578Bst), and in healthy and cancerous breast tissues. Molecular (Western blot and RT-PCR) and immunohistochemical techniques were used to investigate the LFG expression. To investigate the breast cancer cell proliferation in the presence of Fas, we performed fluorescent cell viability assays. The possible association of Fas with LFG was analyzed by immunofluorescence microscopy. In this paper, we provide convincing evidence that LFG is overexpressed in several human breast cancer cell lines. More importantly, we found that the LFG expression correlates with high tumour grades in primary breast tumours. Finally, we demonstrated that Fas sensitivity is reduced in breast cancer cell lines expressing LFG. Our results indicated that LFG is strongly expressed in breast cancer epithelial cells. Moreover, the overexpression of LFG correlated with tumour grade and reduced Fas sensitivity. Our findings support the idea that LFG may have a role in the downregulation of apoptosis in breast cancer cells.",
  "full_text": "Cell Mol Biol Lett Cell. Mol. Biol. Lett Cellular & Molecular Biology Letters 1425-8153 1689-1392 SP Versita Heidelberg 6275920 20336406 9 10.2478/s11658-010-0009-1 Research Article The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues Bucan Vesna 0511-532-8856 0511-532-8890 Bucan.vesna@mh-hannover.de 1 2 Reimers Kerstin 1 Choi Claudia Yu 1 Eddy Mau-Thek 1 Vogt Peter M. 1 1 grid.10423.34 0000000095299877 Department of Plastic, Hand and Reconstructive Surgery, Medical School of Hannover, Podbielskistraße 380, D-30659 Hannover, Germany 2 grid.10423.34 0000000095299877 Abteilung für Plastische, Hand- und Wiederherstellungschirurgie, Medizinische Hochschule Hannover, Carl-Neubergstr. 1, 30625 Hannover, Germany 19 3 2010 6 2010 15 2 296 310 7 10 2009 4 3 2010 © © Versita Warsaw and Springer-Verlag Wien 2010 Lifeguard (LFG) is an anti-apoptotic protein that inhibits Fas-mediated death in tumour cells. However, the molecular function of human LFG in the carcinogenesis of human breast cells is uncertain. We studied the expression and function of endogenous LFG in four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D and HS 578T), a human breast epithelial cell line (HS 578Bst), and in healthy and cancerous breast tissues. Molecular (Western blot and RT-PCR) and immunohistochemical techniques were used to investigate the LFG expression. To investigate the breast cancer cell proliferation in the presence of Fas, we performed fluorescent cell viability assays. The possible association of Fas with LFG was analyzed by immunofluorescence microscopy. In this paper, we provide convincing evidence that LFG is overexpressed in several human breast cancer cell lines. More importantly, we found that the LFG expression correlates with high tumour grades in primary breast tumours. Finally, we demonstrated that Fas sensitivity is reduced in breast cancer cell lines expressing LFG. Our results indicated that LFG is strongly expressed in breast cancer epithelial cells. Moreover, the overexpression of LFG correlated with tumour grade and reduced Fas sensitivity. Our findings support the idea that LFG may have a role in the downregulation of apoptosis in breast cancer cells. Key words Apoptosis Lifeguard Fas Breast cancer issue-copyright-statement © © Versita Warsaw and Springer-Verlag Wien 2010 Abbreviations used BI-1 Bax inhibitor-1 DAPI 4’, 6’-diamidino-2-phenylindole EDTA ethylenediaminetetraacetic acid EGF epidermal growth factor FCS fetal calf serum LFG Lifeguard RT-PCR reverse transcribed polymerase chain reaction PMSF phenylmethyl sulfonyl fluoride PVDF polyvinylidene fluoride References 1. Reed J.C. Mechanisms of apoptosis Am. J. Pathol. 2000 157 1415 1430 11073801 2. Sjostrom J. Bergh J. How apoptosis is regulated, and what goes wrong in cancer BMJ 2001 322 1538 1539 10.1136/bmj.322.7301.1538 11420280 3. Boise L.H. Gonzalez-Garcia M. Postema C.E. Ding L. Lindsten T. Turka L.A. Mao X. Nunez G. Thompson C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death Cell 1993 74 597 608 10.1016/0092-8674(93)90508-N 8358789 4. Boyd J.M. Gallo G.J. Elangovan B. Houghton A.B. Malstrom S. Avery B.J. Ebb R.G. Subramanian T. Chittenden T. Lutz R.J. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins Oncogene 1995 11 1921 1928 7478623 5. Oltvai Z.N. Milliman C.L. Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 1993 74 609 619 10.1016/0092-8674(93)90509-O 8358790 6. Yang E. Zha J. Jockel J. Boise L.H. Thompson C.B. Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death Cell 1995 80 285 291 10.1016/0092-8674(95)90411-5 7834748 7. Certo M. Del G.M. Nishino M. We I.G. Korsmeyer S. Armstrong S.A. Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members Cancer Cell 2006 9 351 365 10.1016/j.ccr.2006.03.027 16697956 8. Uren R.T. Dewson G. Chen L. Coyne S.C. Huang D.C. Adams J.M. Kluck R.M. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak J. Cell. Biol. 2007 177 277 287 10.1083/jcb.200606065 17452531 9. Willis S.N. Fletcher J.I. Kaufmann T. van Delft M.F. Chen L. Czabotar P.E. Ierino H. Lee E.F. Fairlie W.D. Bouillet P. Strasser A. Kluck R.N. Adams S.M. Huang D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak Science 2007 315 856 859 10.1126/science.1133289 17289999 10. Yethon J.A. Epand R.F. Leber B. Epand R.M. Andrews D.W. Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis J. Biol. Chem. 2003 278 48935 48941 10.1074/jbc.M306289200 14522999 11. Chipuk J.E. Kuwana T. Bouchier-Hayes L. Droin N.M. Newmeyer D.D. Schuler M. Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 2004 303 1010 1014 10.1126/science.1092734 14963330 12. Orrenius S. Apoptosis: molecular mechanisms and implications for human disease J. Intern. Med. 1995 237 529 536 10.1111/j.1365-2796.1995.tb00881.x 7782723 13. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease Science 1995 267 1456 1462 10.1126/science.7878464 7878464 14. Reed J.C. Pellecchia M. Apoptosis-based therapies for hematologic malignancies Blood 2005 106 408 418 10.1182/blood-2004-07-2761 15797997 15. Oltersdorf T. Elmore S.W. Shoemaker A.R. Armstrong R.C. Augeri D.J. Belli B.A. Bruncko M. Deckwerth T.L. Dinges J. Hajduk P.J. Joseph M.K. Kitada S. Korsmeyer S.J. Kunzer A.R. Letai A. Li C. Mitten M.J. Nettesheim D.G. Ng S. Nimmer P.M. O’Connor J.M. Oleksijew A. Petros A.M. Reed J.C. Shen W. Tahir S.K. Thompson C.B. Tomaselli K.J. Wang B. Wendt M.D. Zhang H. Fesik S.W. Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 677 681 10.1038/nature03579 15902208 16. Haldar S. Negrini M. Monne M. Sabbioni S. Croce C.M. Down-regulation of bcl-2 by p53 in breast cancer cells Cancer Res. 1994 54 2095 2097 8174112 17. Hollstein M. Sidransky D. Vogelstein B. Harris C.C. p53 mutations in human cancers Science 1991 253 49 53 10.1126/science.1905840 1905840 18. Ikegaki N. Katsumata M. Minna J. Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells Cancer Res. 1994 54 6 8 8261463 19. Liang X.H. Mungal S. Ayscue A. Meissner J.D. Wodnicki P. Hockenbery D. Lockett S. Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53 J. Cell Biochem. 1995 57 509 521 10.1002/jcb.240570316 7768985 20. McDonnell T.J. Troncoso P. Brisbay S.M. Logothetis C. Chung L.W. Hsieh J.T. Tu S.M. Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res. 1992 52 6940 6944 1458483 21. Yang Q. Sakurai T. Yoshimura G. Suzuma T. Umemura T. Nakamura M. Nakamura Y. Mori I. Kakudo K. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy Oncol. Rep. 2003 10 121 125 12469156 22. Yang Q.F. Sakurai T. Yoshimura G. Shan L. Suzuma T. Tamaki T. Umemura T. Kokawa Y. Nakamura Y. Nakamura M. Tang W. Utsunomiya H. Mori I. Kakudo K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma Breast Cancer Res. Treat. 2000 61 211 216 10.1023/A:1006474307180 10965997 23. Fernandez M. Segura M.F. Sole C. Colino A. Comella J.X. Cena V. Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment J. Neurochem. 2007 103 190 203 17635665 24. Somia N.V. Schmitt M.J. Vetter D.E. Van Antwerp D. Heinemann S.F. Verma I.M. LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death Proc. Natl. Acad. Sci. USA 1999 96 12667 12672 10.1073/pnas.96.22.12667 10535980 25. Jean J.C. Oakes S.M. Joyce-Brady M. The Bax inhibitor-1 gene is differentially regulated in adult testis and developing lung by two alternative TATA-less promoters Genomics 1999 57 201 208 10.1006/geno.1999.5761 10198159 26. Xu Q. Reed J.C. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast Mol. Cell 1998 1 337 346 10.1016/S1097-2765(00)80034-9 9660918 27. Reimers K. Choi C.Y. Mau-Thek E. Vogt P.M. Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family Int. J. Mol. Med. 2006 18 729 734 16964429 28. Schweitzer B. Taylor V. Welcher A.A. McClelland M. Suter U. Neural membrane protein 35 (NMP35): a novel member of a gene family which is highly expressed in the adult nervous system Mol. Cell Neurosci. 1998 11 260 273 10.1006/mcne.1998.0697 9698393 29. Schweitzer B. Suter U. Taylor V. Neural membrane protein 35/Lifeguard is localized at postsynaptic sites and in dendrites Brain Res. Mol. Brain Res. 2002 107 47 56 10.1016/S0169-328X(02)00445-X 12414123 30. Plati J. Bucur O. Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities J. Cell Biochem. 2008 104 1124 1149 10.1002/jcb.21707 18459149 31. Melet A. Song K. Bucur O. Jagani Z. Grassian A.R. Khosravi-Far R. Apoptotic pathways in tumor progression and therapy Adv. Exp. Med. Biol. 2008 615 47 79 10.1007/978-1-4020-6554-5_4 18437891 32. Sturm I. Papadopoulos S. Hillebrand T. Benter T. Luck H.J. Wolff G. Dörken B. Daniel P.T. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene Int. J. Cancer 2000 87 517 521 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B 10918191 33. Soufla G. Baritaki S. Sifakis S. Zafiropoulos A. Spandidos D.A. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix Int. J. Biol. Markers 2005 20 18 27 15832769 34. Bargou R.C. Daniel P.T. Mapara M.Y. Bommert K. Wagener C. Kallinich B. Royer H.D. Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis Int. J. Cancer 1995 60 854 859 10.1002/ijc.2910600622 7896458 35. Haldar S. Negrini M. Monne M. Sabbioni S. Croce C.M. Down-regulation of bcl-2 by p53 in breast cancer cells Cancer Res. 1994 54 2095 2097 8174112 36. Leek R.D. Kaklamanis L. Pezzella F. Gatter K.C. Harris A.L. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer Br. J. Cancer 1994 69 135 139 8286195 37. Stark A.M. Pfannenschmidt S. Tscheslog H. Maass N. Rosel F. Mehdorn H.M. Held-Feindt J. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation Neurol. Res. 2006 28 787 793 10.1179/016164106X110364 17288732 38. Krajewski S. Blomqvist C. Franssila K. Krajewska M. Wasenius V.M. Niskanen E. Nordling S. Reed J.C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Res. 1995 55 4471 4478 7671262 39. Grzmil M. Thelen P. Hemmerlein B. Schweyer S. Voigt S. Mury D. Burfeind P. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells Am. J. Pathol. 2003 163 543 552 12875974 40. Grzmil M. Kaulfuss S. Thelen P. Hemmerlein B. Schweyer S. Obenauer S. Kang T.W. Burfeind P. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells J. Pathol. 2006 208 340 349 10.1002/path.1902 16353131 41. Tanaka R. Ishiyama T. Uchihara T. Inadome Y. Iijima T. Morishita Y. Kano J. Goya T. Noguchi M. Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma Cancer 2006 106 648 653 10.1002/cncr.21639 16353209 42. Villalva C. Trempat P. Greenland C. Thomas C. Girard J.P. Moebius F. Delsol G. Brousset P. Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma Br. J. Haematol. 2002 188 791 798 10.1046/j.1365-2141.2002.03671.x 43. Reimers K. Choi C.Y. Bucan V. Vogt P.M. The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis Curr. Mol. Med. 2008 8 148 156 10.2174/156652408783769562 18336295 44. Esseghir S. Reis-Filho J.S. Kennedy A. James M. O’Hare M.J. Jeffery R. Poulsom R. Isacke C.M. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts J. Pathol. 2006 210 420 430 10.1002/path.2071 17054309 45. Nagata S. Golstein P. The Fas death factor Science 1995 267 1449 1456 10.1126/science.7533326 7533326 46. Hengartner M.O. The biochemistry of apoptosis Nature 2000 407 770 776 10.1038/35037710 11048727 47. Landowski T.H. Gleason-Guzman M.C. Dalton W.S. Selection for drug resistance results in resistance to Fas-mediated apoptosis Blood 1997 89 1854 1861 9058704 48. Toillon R.A. Descamps S. Adriaenssens E. Ricort J.M. Bernard D. Boilly B. Le Bourhis X. Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling Exp. Cell Res. 2002 275 31 43 10.1006/excr.2002.5490 11925103",
  "plain_text": "Lifeguard (LFG) is an anti-apoptotic protein that inhibits Fas-mediated death in tumour cells. However, the molecular function of human LFG in the carcinogenesis of human breast cells is uncertain. We studied the expression and function of endogenous LFG in four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D and HS 578T), a human breast epithelial cell line (HS 578Bst), and in healthy and cancerous breast tissues. Molecular (Western blot and RT-PCR) and immunohistochemical techniques were used to investigate the LFG expression. To investigate the breast cancer cell proliferation in the presence of Fas, we performed fluorescent cell viability assays. The possible association of Fas with LFG was analyzed by immunofluorescence microscopy. In this paper, we provide convincing evidence that LFG is overexpressed in several human breast cancer cell lines. More importantly, we found that the LFG expression correlates with high tumour grades in primary breast tumours. Finally, we demonstrated that Fas sensitivity is reduced in breast cancer cell lines expressing LFG. Our results indicated that LFG is strongly expressed in breast cancer epithelial cells. Moreover, the overexpression of LFG correlated with tumour grade and reduced Fas sensitivity. Our findings support the idea that LFG may have a role in the downregulation of apoptosis in breast cancer cells."
}
